## Index

| ABCE models | 18 |
| Abuja Goals Fund | see AGF |
| AD (auto-disposable syringes) | 81, 83 |
| transmission probability | 83 |
| Addis Ababa conference | see Civil Society Panel |
| Addis Ababa Youth Forum Prioritization | 347 |
| adolescent sexual activity | 239, 241, 251–2, 254, 258, 260–1, 269–70, see also keeping girls in school |
| Afrobarometer project | 227, 230–1, 252 |
| age factors | 20–1 |
| AGF (Abuja Goals Fund) | 6, 183, 184, 186, 201–5, 206, 222, 229–33, 344, 346, 347 |
| AIDS | death averted costs | 306–7 |
| denial by politicians | 234, 235 |
| epidemiology | 301 |
| funding | 342 |
| future scenarios | 304–5 |
| R&D see vaccine research and development |
| retro-virus discovered | 61, see also ART |
| trials | 314–18 |
| vaccine | 7 |
| AIDS in the Twenty-First Century: Disease and Globalisation | 68 |
| AIDS: Taking a Long-Term View | 2 |
| AIDS vaccine | accelerating development | 309–12, 346, 347 |
| access to | 325 |
| alternatives to | 326 |
| benefit-cost ratios | 310, 321, 326 |
| benefits | 309 |
| costs | 305–6, 321, 322–3 |
| in sub-Saharan Africa | 306 |
| disinhibition | 146, 324–5 |
| effectiveness | 323–4 |
| and epidemic future | 324 |
| paying for | 325–6 |
| research | 330 |
| societal benefits | 321 |
| synergistic benefits | 325 |
| aids2031 Consortium | xx, 2 |
| Modeling Working Group | xix |
| AIDSCost projection program | 128, 147 |
| AIM (AIDS Impact Model) | 78–9, 89–90, 96–7 |
| alcohol | abuse as HIV epidemic driver | 285 |

| Laffer Curve | 244 |
| problematic use of | 239, 242–5 |
| substitution | 244 |
| Angola | alcohol tax | 262–3 |
| blood supply testing | 86 |
| HIV epidemic scale | 65–6 |
| HIV incidence/prevalence | 13 |
| key indicators | 115–16 |
| anthropometric outcomes | 55 |
| Appel, Jacob | 191 |
| ART (anti-retroviral treatment) | access to treatment | 125, 140–1, 181, 185, 233–4 |
| AIDSCost projection program | 128, 147 |
| anti-retroviral prophylaxis options | 109–10, 122 |
| at-risk groups targeting strategy | 312 |
| and behavioral responses | 50–1 |
| benefit-cost analyses |
| for successful infection prevention treatment | 159–60 |
| for unsuccessful infection prevention treatment | 156 |
| benefit-cost ratios | 76, 77–8, 137, 138–9, 143, 145, 178–82 |
| benefit-cost results | 141–2, 146–8 |
| best treatment stage | 125–6 |
| CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 178 |
| CD4 counts and eligibility | 181 |
| cost-effectiveness | 141–2 |
| costs | 32, 77, 126–7, 145, 169, 178 |
| coverage | 128 |
| and family planning | 222 |
| drug costs | 308 |
| and dynamics of HIV infection | 103–4 |
| eligibility guidelines | 213–14 |
| extension of 15 |
| feedback effects | 219–20 |
| future cost per patient | 178–9 |
| historical counterfactual | 135 |
| HIV transmission models | 79–81, 131–3 |
| incremental spending | 140 |
| infections reduction incremental benefits | 194 |
| life years gained | 179–81, 184 |
| lifelong treatment | 109–10, 112 |
| mother-to-child infections | 75 |
national uptake rate 128
Nobel Laureate Economist Expert Panel findings on 339
non-AIDS mortality rate 180
numbers treated by 1
oral 301
patient life expectancy 138–9
and prevention techniques 70
primary infection prevention 159
scaling-up benefits 181, 346, 347
scaling-up enrollment 343, 347–8
secondary infection prevention 159
simulated scenarios 135–7
spillover benefits 145
statistics provision 79
in sub-Saharan Africa xix
sufficient damage factor 127
survival years 180–1
TDF/FTC combination 54
uptake projection 139–40
value of lives saved 78
zero uptake 135, 136
benefit estimates 103–4
benefit-cost analyses 21, 23
continued investment 308–9
DALYs (disability-adjusted life years) 20, 22, 26–9,
32–3, 34–40, 41–2, 49, 62, 226
decline in World Bank 190
dynamic framework time representation 155–60
HC (Human Capital) approach 170
HIV treatment pre-pregnancy 164–6
information campaigns (IC) 25–6
and interventions 108
life-cycle perspective 26, 30, 62
Nobel Laureate Economist Expert Panel findings on 337
for policy interventions 26–32
discounting 31
estimation challenges 31–2
general considerations 26–30
interaction among solutions 31
prices 30
range of costs 31
range of impacts 30
scale 31
for successful infection prevention treatment 159–60
and unrecognized metaphors 281
for unsuccessful infection prevention treatment 156
vaccine research and development 304–9
WTP (willingness to pay) 170–1
benefit-cost ratios 5, 36–7, 40–1, 181–2, 189
AIDS vaccine development 310
ART 32, 76, 77–8, 137, 138–9, 143, 145, 146–8, 178–82
and ARV provision 173
CCTs 220–2
CD4 cell count 158–60
community health 198
cross-country variations 293
discounted/undiscounted 156, 175
health system strengthening 208
HIV reduction interventions 34–7, 41–2, 63–4, 174, 293
infections averted 32
interventions 260–3
males circumcision 36–7, 40–1, 63–4, 339
pMTCT in sub-Saharan Africa 160–1, 163, 174–5
procedures summary 32–3
treatment costs 32
unit costs 294–5
varying average costs 294–5
VSL (Value of a Statistical Life) approach 170–1
Benin
alcohol tax 262–3
blood supply testing 86
HIV incidence/prevalence 13, 114–17
key indicators 115–16
problems faced by government (Afrobarometer) 232
blockbuster drugs 303
blood safety intervention 186
blood transfusions 4, 74, 86–8, 89, 102–3, 346, 347
Bloom, David 5–6
BMGF (Bill and Melinda Gates Foundation) 213
body undergoing treatment metaphor 283–4
Bollinger, Lorri 4, 102, 105, 121, 169–70, 171, 259, 347–8
Botswana
  alcohol tax 262–3
  health priority survey 230–1
  HIV epidemic scale 65–6
  HIV incidence/prevalence 12, 13, 29, 30, 34, 39–40
  key indicators 115–16
  life expectancy with/without AIDS 162
  male circumcision 25, 40–1
  problems faced by government (Afrobarometer) 232
  resources allocated to 15–17
  unmet need for family planning 165
Brandeau, M. L. 295
Brazil, AIDS vaccine 325
Brent, Robert 5
British Columbia Center for Excellence on HIV/AIDS 69–70
Burkina Faso
  Abuja target 202
  alcohol tax 262–3
  HIV incidence/prevalence 13, 114–17
  key indicators 115–16
  life expectancy with/without AIDS 162
  unmet need for family planning 165
Burundi
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  life expectancy with/without AIDS 162
  unmet need for family planning 165
bush circumcisions 52
Cambodia, conditional cash transfers 254
Cameroon
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  life expectancy with/without AIDS 162
  unmet need for family planning 165
Campbell Collaboration 65
cancer as investment priority 189
canine distemper, and vaccine research and development 313
Cape Verde, problems faced by government (Afrobarometer) 232
CAPRISA (Centre for the AIDS Programme of Research in South Africa) 64
CAPRISA Study 54
cash incentive programs see CCT
CBA (cost-benefit analysis) see benefit-cost analyses
CCT (conditional cash transfer) 21, 23, 31, 53, 54–8, 191–3, 218
benefit-cost ratios 220–2
conceptual foundations of 56
current evidence on 57–8
female education 245
and HIV awareness 192
and HIV testing 228–9
and infection reduction 222
and joint objectives 184
keeping girls in school see keeping girls in school
potential impacts of 186
rationale for 54–7
RESPPECT study 193
CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 172, 173, 178, 199
cell count and ART eligibility 181
cell count benefit-cost ratios 158–60
and death probability 180–1
point of care dipssticks 179
screening 161
CEA see cost-effectiveness analyses
Central African Republic
  alcohol tax 262–3
  health worker shortage 196
  HIV incidence/prevalence 13, 196
  key indicators 115–16
  life expectancy with/without AIDS 162
Chad
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  unmet need for family planning 165
CHOAHA program 248–9
childhood diseases, as investment priority 189
Chimeric Venezuelan Equine Encephalitis 313
China, conditional cash transfers (one-child policy) 191
CHWs (community health workers)
deployment 216, 218
Technical Task Force 186, 196, 197–9
training costs/benefits 220–2
COD (cash on delivery)
cryptococc meningitis (CM) 183, 200–1, 206, 216, 218, 220, 340
Cryptococcosis neoformans 184, 199–201
cultural practices, as HIV epidemic driver 285
Cytomegalovirus Clinical Development Program 313
DALYs (disability-adjusted life years) 20, 22, 26–9, 34–40, 41–2, 49, 62, 63–4, 75–6, 104, 170–1, 175–6, 189–90, 197, 200, 203, 205, 206, 207, 226, 243, 260, 263–5, 349
country 271–2
incremental cost 274–5
parameters 260–1
DCP2 190–1
dead metaphors 282
deaths averted 188–9, 194, 202, 203, 204, 306–7, 308
demiProj software tool 78
diagnostic tests 300
discounting 171–2, 173, 175, 189–90, 200, 263, 333
disinhibition 146, 324–5, 339
djibouti
Abuja target 202
key indicators 115–16
DMPTT see Male Circumcision: Decision Makers’ Program Planning Tool
donor support flat-lining 213–14
dose-response 284
drug costs 126–7, 308
drug development 300
drug supply systems intervention 186
drug users, injecting 92–5
Duflo, Esther 191
Earth Institute Technical Taskforce 195
ecology of risk 285, 286
The Economist, end of AIDS? 12
Efavirenz 111, 126
effectiveness estimates 103–4
efficiency solution 188
embodiment of social conditions 287–8
emergency rescue intervention 186
epidemic model 295
EPP (Estimation and Projection Package) 78
Equatorial Guinea
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
OIs (opportunistic infections) 76–7, 78
unmet need for family planning 165
cotrimoxazole prophylaxis 161
Couple-based HIV testing 20
CRAG (cryptococcal antigen)
costs and benefits 186, 200–1, 208
testing 199–200, 201, 228
critical enablers 188–9
cross-intervention benefits 347

and Abuja Goals Fund (AGF) 201–5, 206, 229–33
donor assistance 184
to governments 218
Collier, Paul 337–8
combination prevention 145
commodity approach to strategies 15
Community health workers 183, 184, 206, 207, 228
Community mobilization 248–9, 253, 255, 259, 265, 267, 268, 269–70, 293
Community Systems Strengthening Framework 235
Comoros
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Concurrent sexual partners, as HIV epidemic driver 285
Condoms 11, 19, 51, 56, 68, 170, 248
Congo
Abuja target 202
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
unmet need for family planning 165
Contraception, unmet need for 164
See also: Condoms; Family Planning
Copenhagen Consensus 2–3, 7, 8, 71
Copenhagen Consensus Center, global development project (2008) 2
Copenhagen Consensus Challenge paper 245
Copenhagen Consensus project (2004) 2
cost-effectiveness xx, 11, 17–23, 37–9, 49, 58
Blood transfusions 74, 86–8
ICER (incremental cost-effectiveness ratio) 75–6
Injecting drug users 92–5
Interventions 17–23, 242–5, 260
Medical injections 74, 81–6
Mother-to-child transmission 74, 121
in Sub-Saharan Africa 11, 20, 104
cost-effectiveness analyses 22, 283
and unrecognized metaphors 281
cost estimates 103
Cost per death 194, 198
cost per infection 104
Cote d’Ivoire
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Life expectancy with/without AIDS 162
OIs (opportunistic infections) 76–7, 78
Unmet need for family planning 165
Cotrimoxazole prophylaxis 161
Couple-based HIV testing 20
CRAG (cryptococcal antigen)
costs and benefits 186, 200–1, 208
testing 199–200, 201, 228
critical enablers 188–9
cross-intervention benefits 347

© in this web service Cambridge University Press
www.cambridge.org
Ethiopia (cont.)

key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
Millennium Village Project (MVP) 247
PEPFAR-funded interventions 255
unmet need for family planning 165
Voices of the Poor project 196
evidence-based allocation strategy 17–18
external validity of interventions 294

faith-based abstinence 68
family planning 97, 117, 161, 163–4, 197, 198, 202, 222
cost-effectiveness of 164, 198–9
social benefits 164
unmet need for in sub-Saharan Africa 165
Farm Input Subsidy Programme 247
FDA, and microbicide 64
FEM-PrEP trial 54
female education 245
female sex workers 296–7
FFS (Farmer Field School) 247, 252
first-line treatment benefits/costs 157
flat-lining donor support 213–14
Forstyh, Stephen 7
funding 1
alternative use for 214–15
competing demands 213–14

G8 (Gleneagles 2005) 185
Gabon
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
Gambia
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
Gardasil 322, 323, 325
GAVI Alliance 184–6
gender inequalities, as HIV epidemic driver 285
gender role perceptions/training 239, 240, 246–7, 248–9, 252, 254–5, 258–9, 263, 267, 269–70, 293
general structure (GS) interventions 216–18, 221
genital lesions 285
Georgetown University Expert Panel see Nobel Laureate Economicist Expert Panel
GFATM see Global Fund to Fight AIDS, Tuberculosis and Malaria
Ghana
alcohol tax 262–3
health priority survey 230–1
HIV incidence/prevalence 13, 114–17
HIV/AIDS stigma 248–9
key indicators 115–16
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
unmet need for family planning 165
Voices of the Poor project 196
girls in school 239, 241, 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 343–4
Gleneagles Summit (2006) 125
Global Crises, Global Solutions 184–5, 190
Global Fund Forum 342
Global Fund-hosted Event Prioritization 346
global political commitment, to fighting HIV 213
Global Programme on AIDS 283
GNI per capita statistical life value 189–90
goal-directed thinking 288
Goals and Allocation by Cost-Effectiveness (ABCE) models 18
Goals Model/Goals Express 79–81, 93, 96–7, 259, 265
going upstream metaphor 282–3
Granich, Reuben M. 69–70, 191–2
GS (general structure) interventions 216–18, 221
Guinea
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Guinea-Bissau
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
Gupta, Geeta Rao 286
Halperin, D. T. 19
HCT see HTC
health benefits, advances in estimating 190–1
health care costs, and HIV prevention 307
health care reform, political legitimacy of 231–3
health center upgrade/construction intervention 186
health inequalities and environments 287
health priority survey 230–1
health services strengthening, in rural areas 196–7
health services upgrade 195–9
health spending ratios 187
health system capacity 226–8
health system infrastructure and pMTCT 117–18
health system intervention evaluation 215–17
benefits evaluation 216–17
costs 217
feasibility 215
flexibility 215
intervention level/scope 216
Index 355

technical efficiency 215
time lags/certainty levels 217–18
health system strengthening 213–23, 226–36
access improvement 228
benefit evaluation 216–18
challenges
cost-benefit ratio 208
cost evaluation 217–18
feasibility 215
flexibility 215
intervention evaluation 215–16, 217
intervention scope 216
dynamic models of effect on 152–5
life year value monetization 226
methodological issues 226–33
Nobel Laureate Economist Expert Panel findings on 340
structures 214–15
health workers
shortage 196
skills upgrade 195–9
staff expansion 197–9
heart attacks, as investment priority 189
Hecht, Robert 7
herpes
as epidemic driver 285
and Stepping Stones 246
heterosexual HIV transmission 303
HIA (HIV infection averted) 63–4
high-risk groups 153, 155
HIPC (highly indebted poor countries) initiative 202–3
historical counterfactual 135
HIV
and alcohol consumption 242
in couples 126, 159
deaths statistics xix, 153, 299
dynamic models of effect on 152–5
epidemic drivers 285
epidemic scale 65–6
fatality rate 125
global political commitment to fighting 213
hope and social intervention 288–90
impact modeling 255–9
incidence (of infection) 131
incidence/prevalence ratio 146–8, 213, 226–8
infections averted 255–9, 271–2
modes of transmission 66–7
POC (point-of-care) diagnostic tests 119–21
in women in sub-Saharan Africa 172–3
see also vaccine research and development
HIV counseling, universal 183
HIV information, universal 183
HIV prevention, as investment priority 189
HIV programs, demand side 218
HIV testing
monetization 229
universal 183, 228–9
HIV transmission
heterosexual 303
models 79–81, 131–3
rate estimation 151
in sub-Saharan Africa 238
susceptibility and income inequality 287
HIV treatment
for all women 164–6
benefits of prevention 306–8
costs 70
efficiency 215
immediacy 70
individual effects 70
population effects 70
programs’ integration with primary health care 214–15
selective expansion 214–15
selective integration 214–15
stand-alone programs 215
see also ART (anti-retroviral treatment); HSS (health system strengthening)
HIV vulnerability, social drivers 239
HIV-infected children, survival rate 77
HIV/AIDS
R&D see vaccine research and development
spending and health systems strengthening 186–7
HIVNS (HIV-focused non-structural) interventions 216–18, 221
HLT (High Level Taskforce on International Innovative Financing for Health Systems) 185, 195, 202–3
Hontelez, Jan 5
hope
analytical advantages 289
as diagnostic tool 289–90
and income 289
and optimism 288
and palliative care 289
and social intervention 288–90
HSS (health systems strengthening) 184, 186–7, 204–5
expansion of 214–15
and health worker skills upgrade 195–9
intervention scale 219
interventions implementation time 219
potential of 215
priority setting 220
targeting vulnerable populations 220
unintended consequences 218–19
HTC (HIV testing and counseling) 14–15, 19–20, 22–3, 25, 41–2
benefits of 49–50, 62–3
and Civil Society Panel 344
cost-benefit ratio 63–4
cost-effectiveness 37
costs of 33–4
and HIV incidence 33–4
as prevention 69–70, 192–3
treatment as prevention 166–8
uptake at community level 248
Humair, Sal 6
human resources training intervention 186
human rights and conditional cash transfers 191
hyperbolic discounting 190
IAVI (International AIDS Vaccine Initiative) 299, 305–6
research developments source 313
IC (information campaigns) 20, 25–6, 34, 41–2, 49–50, 52–3, 62, 63–4, 70–1
ICASA 341, 346
ICD (infectious and communicable diseases) 188
ICER (incremental cost-effectiveness ratio) 75–6
IDU (injecting drug use) interventions 92–5, 96, 102–3, 104, 105
IeDEA Consortium 180
ICP+ (International Health Partnerships) 184–5, 195, 202–3, 204–5
IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247, 252, 254–5, 258–9
immunodeficiency virus 20–1
impact evaluations 50
inappropriate metaphors 281–8
income inequality and poverty/transmission susceptibility 287
incremental benefits 194
incremental spending results 140
India, conditional cash transfers (vasectomy grants) 191
individual behavior
environment as regulator of 286–7
and risk environments 286
infant HIV exposure diagnosis 161
infant infections 188, 198
infant lives saved 207
infant mortality 203, 204
infants, as most valued lives 190
infection probability model 79–81
information technology intervention 186
initiation schools 52
injecting drug users 75, 92–5
Institute for Health Metrics and Evaluation 332
intergenerational sexual behavior as HIV epidemic driver 285
intergenerational transmission of disease 33, 285
International Conference on AIDS (ICASA) 341, 346
International Group on Analysis of Trends in HIV Prevalence and Behaviors in Young People in Countries most Affected by HIV (2010) 19
International HIV/AIDS Alliance 248–9
interventions
adolescent sexual activity 239, 241, 245, 247, see also keeping girls in school
AGF (Abuja Goals Fund) see AGF
alcohol
problematic use of 239, 242–5
taxation see alcohol taxation
anthropometric outcomes 55
beneficiaries of 105
benefit-cost ratios 260–3
and CBA (cost-benefit analysis) 108, 242–5
CCT (conditional cash transfer) see CCT (conditional cash transfer)
community mobilization see community mobilization cost-effectiveness 17–23, 242–5, 260
criteria for 61–2
cross-intervention benefits 347
demand-side 55, 245
effectiveness 17–23, 242–5
evidence-based allocation strategy see gender roles
perception/training
GS (general structure) 216–18
HIV infection reduction 34–9, 255–9
HIV reduction benefit-cost ratios 34–7, 41–2, 63–4, 174
HIV treatment issues 70
and HIV vulnerability social drivers 239
HVNS (HIV-focused non-structural) 216–18, 221
and hope 288–90
HSS (health systems strengthening) objectives 186
scale 219
IDU 92–5
IMAGE see IMAGE
impact evaluations 50
implementation time 219
investment priorities 189
keeping girls in school see keeping girls in school
local diagnosis 289
location-specific 15–17
long-lasting 222
and MSM 53
Nobel Laureate Economist Expert Panel findings 337–8
and orphan care costs 311
pMTCT (mother-to-child transmission) 109–13, 118, 121, 151, 160–6
and population size 17
potential behavioral responses 50–2
potential beneficiaries 39–41
pre-exposure chemoprophylaxis 53, 54
preventative vs treatment 104–5
prevention efficiency 52–3
priority setting 220
sexually transmitted infections 30
Stepping Stones 246, 258–9
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 255, 265
structural interventions 286
target populations 220, 247, 248–9
targeted approaches 53
and technologies/strategies 329
total costs per country 272–3
transferable social policy 283–4
trusted interventions 19
unit costs per country 272–3
vulnerable populations 220
investment approach to strategies 15, 17, 21
six program components 15
iPrEx study 54
IPV (intimate partner violence) 265
irresponsible sexual behavior as HIV epidemic driver 285
Jambison, Dean 7, 189
Johri, Mira 5
Karlan, Dean 51
Kazianza, Harounan 6–7
keeping girls in school 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 293, 294, 343–4, 346, 347
Kenrnon 51
Kenya
alcohol tax 262–3
alcohol taxation 244
ART cures 51
development indicators 227
family planning unmet needs 165
health priority survey 230–1
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 66–7, 296–7
IDU (injecting drug use) interventions 92–5, 96–7
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
male circumcision 23–5
Millennium Village Project (MVP) 247
needle-sharing infections 74
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
unmet need for family planning 165
liability and cost ratio 323
Liberia
Abuja target 202
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
life expectancy 161, 169
life insurance 6–7
incentivization 296–7
life-cycle perspective 26, 30, 62
life-year costs 145
life-year values 137, 164, 170–1, 188–9
monetization 226
life-years gained 179–81, 188, 200, 307
LiST software tool 78
location-specific interventions 15–17
LoveLife campaign 70
McGreevey, William 5–6
Madagascar
alcohol tax 262–3
health priority survey 230–1
HIV incidence/prevalence 13
key indicators 115–16
problems faced by government (Afrobarometer) 232
Makhwapheni Campaign 70–1
Making Services Work for Poor People 233
malaria, as investment priority 189
Malawi
alcohol tax 262–3
cash incentive programs 21, 57–8
CCTs (conditional cash transfers) 192–3, 245
keeping girls in school 245, 254, 258
development indicators 227
donor money corruption 231
family planning 197
Farm Input Subsidy Programme 247
GNI per capita 226–8
health priority survey 230–1
health workers 196, 228
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 34, 196
HIV and sexual contact 14
key indicators 115–16
life expectancy 226–8
with/without AIDS 162
male circumcision 23–5
Millennium Village Project (MVP) 247
PBI (performance-based incentive) 192
problems faced by government (Afrobarometer) 232
SIHR (Schooling, Income, and HIV Risk) study 193
unmet need for family planning 165
Voices of the Poor project 196
male circumcision see MC
Mali
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
problems faced by government (Afrobarometer) 232
mass media IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63, 70–1
maternal health and child survival 111
maternal mortality 197, 198, 202
Mauritania
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Mauritius
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
IDU (injecting drug use) infection 92–5
key indicators 115–16
MBB (marginal budgeting for bottlenecks) 185, 203
Mbeki, President Thabo 234, 235
MC (male circumcision) 4, 12, 15, 18, 21, 22–5, 41–2, 49–50, 300, 301, 346
benefit-cost ratios 36–7, 40–1, 63–4, 339
bush circumcision 52
cost-effectiveness of 58, 62
costs of 33
as high priority 348
infant 339, 348
and infection prevention 326
intervention efficiency 52–3
intervention requirements 39–41
key issues 69
lack of as HIV epidemic driver 285
long-term benefits 25–6, 62, 66, 68–9
Male Circumcision: Decision Makers’ Program Planning Tool (DMPPT) 18
neonatal 25, 52
uptake and resources 323
MDGs see Millennium Development Goals
Medecins Sans Frontiers 159
medical injections 4, 74, 81–5, 86, 102–3
medical male circumcision see MC
Mema wa Vijana intervention 255
men who have sex with men see MSM
Menberu, Retta 341, 343, 345
Merck vaccine failure 302
metaphorical language in social policy interventions 281–90
metaphors
and cost-effective analyses 281
inappropriate 281–8
risk behavior 284–6
structural drivers 284–6
unexamined 281–6
unrecognized 281
Mexico, conditional cash transfers 191, 254
microbicides and HIV risk 64, 71
microfinance schemes 21, 246, 247
Millennium Development Goals
failure to achieve 341
Goal 4 (reduce child mortality) 121–2
Goal 5 (improve maternal health) 121–2
Goal 6 (combat HIV/AIDS) 121–2, 242
Millennium Village Project (MVP) 247, 252
Mills, Anne 185
Mix Market platform 252
modes of transmission 66–7
Montaner, J. S. G. 69–70
moral hazard 146
More than good intentions 191
most-valued persons 189–90
MOT (Modes of Transmission) model 81, 102, 103–4
mother-to-child transmission 4, 5, 74, 75, 77, 88–92, 160–6
anti-retroviral prophylaxis options 109–10, 121
AP (assessment paper) analysis 107, 108, 110–12
CBA (cost-benefit analysis) 108
CD4 screening 161
contraception 164
family planning 117, 161, 163–4
cost-effectiveness of 164
infant HIV exposure diagnosis 161
labor ward screening 118–19
maternal health and child survival 111
maternal mortality 197
multiplex POC (point-of-care) diagnostic tests 119–21
non-health facility births 119
pMTCT cascade 107, 117, 118, 122
potential HIV rates in sub-Saharan Africa 163
analytic timeframe 111–12
benefit-cost reduction 174–5, 342–3
CD4 cell count 110–12, 172
costs and health system infrastructure 113
eliciting 
and HIV prevalence 113
emerging technology 122
forward transmission impact 107, 112
full benefits definition 161
health system infrastructure 117–18
intervention options 109–12, 113, 151
key challenges 113–18
Nobel Laureate Economist Expert Panel findings 342–3
pre-pregnancy 164–6
scaling up 346, 347
services increase requirements 121–2
solutions 118–21
therapeutic options 111, 112, 121
treatment evaluation 172
treatment targets 156
treatment vs family planning 163–4
primary prevention 164
screening tests 161
in sub-Saharan Africa 74, 107, 163
testing and counseling 161
WHO Option A strategies 107–8

Mozambique
alcohol tax 262–3
development indicators 227
health worker shortage 196
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 34, 39–40, 196
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 40–1
problems faced by government (Afrobarometer) 232
unmet need for family planning 165

MSM (men who have sex with men) 4, 53, 66–7, 69, 238

Namibia
alcohol tax 262–3
health priority survey 230–1
HIV incidence/prevalence 13, 34
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 23–5
problems faced by government (Afrobarometer) 232
unmet need for family planning 165

NAT (nucleic acid amplification testing) 86
national epidemics 283
national strategies xx
National Technical Teams (NTTs) 345
Nattrass, Nicoli 6
needle-exchange 105
neonatal circumcision 25, 52
Nevarpine 126, 161–2
Niger
alcohol tax 262–3
blood supply testing 86
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Nigeria
alcohol tax 262–3
development indicators 227
health system capacity 226–8
HIV epidemic scale 65–6
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
Nobel Laureate Economist Expert Panel 337–8
non-sexual HIV transmission prevention
AIDS impact model 78–9

analysis methods 102, 103–4
benefits calculation 76–8
benefits summary 96
blood transfusions 74, 86–8, 102–3
Goals Model/Goals Express 79–81
HIV infections averted model 78
injecting drug users 92–5
medical injections 4, 74, 81–5, 86, 102–3
mother-to-child transmission 4, 5, 74, 88–92, 169–70
multi-country analysis options/limitations 102–3
recommendations 96–7
resource allocation equity 105
NVP (Nevirapine) program 126, 161–2

Ok&G model of infections 152–3
and high-risk groups 155
infection flows 155
with interventions 153–4
transmission mechanism specification 154–5
Odumbe, Ken 341, 342, 345
OIs (opportunistic infections) 76–7, 78, 89, 307, 311

One Million Community Health Workers 195
operations research intervention 186
opiate substitute therapies 105
oppression illness 287
oral anti-retrovirals 311
oral prophylaxis 238
orphan care costs 311
OST (opioid substitution therapy) 75, 105

Padian, N. S. 2
patient transport intervention 186
PBI (performance-based incentive) 192
Pearl Omega 51
Peer Group IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63
pilot studies, external validity of 294
Piot, Peter xx
Platform for Health System Strengthening 195
pMTCT see mother-to-child transmission
POC (point-of-care) diagnostic tests 119–21

Poirier, Dominique 3
poverty as HIV epidemic driver 285, 287
pre-exposure prophylaxis 154, 301
chemoprophylaxis 53, 54, 58
Prescott, Edward C. 337–8
preventative interventions 104–5
Prevention of Non-sexual Transmission Assessment Paper 169–70
primary health care, HIV treatment integration with 214–15
primary infection prevention 159
production function model 295
program enablers 194–5
promiscuous sexual behavior as HIV epidemic driver 285
Protocol G 313
QALYS (quality-adjusted life years) 21–2, 75, 175–6, 349
RAPID software tool 78
Rasmussen, Prime Minister Anders Fogh 2
RBF (results-based financing) 184
RBF (results-based funding) programs 202–3
RCTs (randomized controlled trials) 18–19, 24, 69
and hope studies 289
role of 64–5
and spillover benefits 145–6
Remme, Michelle 6
research intervention 186
RESPECT study 57, 193
RethinkHIV project 11, 21–2, 23, 25–6, 41, 52, 61–2, 65, 74, 76, 77, 104, 108–9, 121–2, 137, 151, 155, 163, 164, 170–1, 174, 175–6, 218, 233, 238, 299, 300, 328, 342
risk behavior 284–6
risk compensation 146
risk ecology 285, 286
risk environments 285
and individual behavior 286
risk-taking behavior patterns 130–1, 133, 146
risk-taking behavior research 56
RNM (Resource Needs Model) 18
Rome International AIDS Conference 238
RP (revealed preference) approach 170
Rush Foundation 2, 7, 8
Rwanda
Abuja target 202
alcohol tax 262–3
HIV awareness 192
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
male circumcision 23–5, 325
OIs (opportunistic infections) 76–7, 78
unmet need for family planning 165
S-I (susceptible-infection) transmission system 152–5
safe blood transfusions see blood transfusions
safe medical injections 81–6
precautions intervention 186
Salomon, Joshua 7
Schelling, Thomas C. 337–8
schistosomiasis 97
schoolgirls see keeping girls in school
secondary infection prevention 159, 311
Sendai virus 313
Senegal
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
problems faced by government (Afrobarometer) 232
sexual abstinence 68, 255
sexual abstinence month 4, 71
sexual behavior, different contexts 283
sexual health; and CM (contingency management) 55–6
sexual infections 11, 41–2, 49
sexual practices, cultural 285
sexual relations
frequency 193
and HIV prevention 11–17, 20, 33, 34–7, 41–2
risk-taking behavior 56–7
see also keeping girls in school
sexually transmitted diseases (STDs) and alcohol 243
HIV 11, 18, 32, 50–2, 63–4, 66–7, 74, 169–70, 238, 300, 339
prevention basics 67–8
see also non-sexual HIV transmission
sexually transmitted infections (STIs) 11, 41–2, 49, 50, 65, 300, 339
as HIV epidemic drivers 285
Sierra Leone
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
SIHR (Schooling, Income, and HIV Risk) study 193
simulated scenarios in ART (anti-retroviral treatment) 135–7
Smith, Vernon L. 337–8
Snyder, Richard 288
social conditions, embodiment of 287–8
social intervention, and hope 288–90
social policy interventions 281–90
Nobel Laureate Economist Expert Panel findings on 339–40
Somalia, key indicators 115–16
Somaliland, Voices of the Poor project 196
South Africa
alcohol tax 262–3
alcohol taxation 243
ART program 217
development indicators 227
GNI per capita 226–8
health system capacity 226–8
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13
HIV testing 195
HIV/AIDS disease statistics 200
HIV/AIDS stigma 248–9
IDU (injecting drug use) intervention 92–5, 96–7
IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247
key indicators 115–16
life expectancy 226–8
with/without AIDS 162
male circumcision 23–5

Medecins Sans Frontiers project 159
microfinance schemes 247
PEPFAR-funded interventions 255
problematic alcohol use 242
problems faced by government (Afrobarometer) 232
TAC (Treatment Action Campaign) 234–5
unmet need for family planning 165
voluntary HIV testing and counseling uptake at community level 248
Spectrum policy models 78–9, 89–90, 93, 96–7, 102, 103–4
spillover benefits 145
SROI (Social Return on Investment) 248–9
SSA see sub-Saharan Africa
stand-alone HIV programs 215
standard dynamic model of infections 152
with interventions 153–4
statistical life value 189–90
Stavudine 126, 174
STDs see sexually transmitted diseases
Stein, Zena 64
Steinberg, Jonny 234
Stepping Stones 246, 258–9
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 248–9, 255, 265
STIs (sexually transmitted infections) 50, 65, 66–7
Stover, John 5
strategies 329
Strengthening Health Systems 5–6
stressors 284
structural drivers metaphor 284–6
structural interventions 286, 287
sub-Saharan Africa
Abuja Goals Fund (AGF) see AGF
age-specific survival 29, 30
AIDS funding 342
AIDS spending and health systems strengthening (HSS) 186–7
AIDS vaccine
 costs 306, 322–3
and epidemic future 324
ART (anti-retroviral treatment) xix
benefits 184
coverage 77–8
BCC (behavioral change communication) 16
behavioral strategies 14–15
benefit-cost ratios for ARV 178–82
benefits of HIV prevention 306–8
blood supply testing 86
CCT programs
effectiveness 55
and keeping girls in school 220–2, 245, 245–2, 254, 258, 293, 294, 343–4
Civil Society Panel see Civil Society Panel
community health workers
costs of 196–7
deployment 183
community mobilization programs 34
cost-effectiveness 11, 20, 104
cryptococcal antigen (CRAG) test 199–201
cryptococcal meningitis 183, 199–201
death avertion 188–9, 194, 203, 204
development indicators 227
family planning see family planning
female sex workers 296–7
financial incentives for 5–6
gender role perceptions 239, 240, 246–7
GNI per capita 75–6
HIV incidence in xix, 1, 12, 19, 29, 30, 34, 39–41, 181, 238
HIV transmission 238
 models 79–81, 131–3
HIV in women 172–3
HIV/AIDS disease statistics 200
HIV/AIDS social policy interventions 281–90
HIV/AIDS solutions 41–2
HTC, home-based 25
ICD (infectious and communicable diseases) 188
incentivizing adults 296–7
income per capita 306
increased health spending 188
infant infections 198
infections and injections 83
interventions see interventions
keeping girls in school see keeping girls in school
key indicators 115–16
labor ward screening 118–19
life expectancy 162, 184
life-year values 137
male circumcision 12, 23–5, 62
maternal mortality 197, 198
modes of transmission 66–7
mother-to-child transmission 74, 107
Nobel Laureate Economist Expert Panel findings 337–8
ObS (opportunistic infections) 76–7, 78
pMTCT benefit-cost ratios 160–1
pMTCT options 112–13
pMTCT services increase requirements 121–2
potential beneficiaries of intervention 39–41
potential HIV rates 163
pre-exposure chemoprophylaxis 53, 54, 58
RethinkHIV project 11
safe blood transfusions 66–8
screening tests 161
sexual relations and HIV prevention 11–17
sexually transmitted HIV 11
Strengthening Health Systems 5–6
testing and counseling 161
treatment cost per person/year 135
UNAIDS spending proposal 205
universal testing, informing, and counseling 183
unmet need for family planning 165
women and HIV 172–3
substance abuse, as HIV epidemic driver 285
Sudan, unmet need for family planning 165
supply chain management 323
<table>
<thead>
<tr>
<th>362</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swaziland</td>
<td>key indicators 115–16</td>
</tr>
<tr>
<td>alcohol tax 262–3</td>
<td>life expectancy with/without AIDS 162</td>
</tr>
<tr>
<td>ARV requirement 174</td>
<td>topical anti-retrovirals 301</td>
</tr>
<tr>
<td>blood transfusion infections 74</td>
<td>topical microbicidies 238</td>
</tr>
<tr>
<td>HIV epidemic scale 65–6</td>
<td>transferable social policy interventions 283–4</td>
</tr>
<tr>
<td>HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 114–17</td>
<td>transmission susceptibility and income inequality 287</td>
</tr>
<tr>
<td>key indicators 115–16</td>
<td>Treatment 2.0 Initiative 5, 174, 179</td>
</tr>
<tr>
<td>life expectancy with/without AIDS 162</td>
<td>treatment interventions 104–5</td>
</tr>
<tr>
<td>male circumcision 23–5</td>
<td>treatment as prevention 166–8, 171–2</td>
</tr>
<tr>
<td>resources allocated to 15–17</td>
<td>treatment resources vs stated goals 213–14</td>
</tr>
<tr>
<td>sexually transmitted HIV 11</td>
<td>treatment unit costs 133–5</td>
</tr>
<tr>
<td>unmet need for family planning 165</td>
<td>TRIPS (Trade-Related Intellectual Property Rights) agreements 168</td>
</tr>
<tr>
<td>unsafe medical injections 74</td>
<td>Tanzania</td>
</tr>
<tr>
<td>synergies with development sectors 188–9</td>
<td>TAC (Treatment Action Campaign) 234–5</td>
</tr>
<tr>
<td>Tanzania</td>
<td>Abuja target 202</td>
</tr>
<tr>
<td>alcohol taxation 244, 262–3, 296</td>
<td>alcohol tax 262–3</td>
</tr>
<tr>
<td>blood supply testing 86</td>
<td>blood transfusion infections 74</td>
</tr>
<tr>
<td>cash incentive programs 57–8</td>
<td>CCTs (conditional cash transfers) 245</td>
</tr>
<tr>
<td>CCTs (conditional cash transfers) 245, 296</td>
<td>development indicators 227</td>
</tr>
<tr>
<td>condoms 170</td>
<td>HIV in couples 126</td>
</tr>
<tr>
<td>cost-effectiveness of HIV prevention 5, 73</td>
<td>HIV epidemic scale 65–6</td>
</tr>
<tr>
<td>development indicators 227</td>
<td>HIV incidence/prevalence 13, 66–7, 81, 324</td>
</tr>
<tr>
<td>HIV epidemic scale 65–6</td>
<td>HIV/AIDS stigma 248–9</td>
</tr>
<tr>
<td>HIV incidence/prevalence 13, 283</td>
<td>infection age 307</td>
</tr>
<tr>
<td>HIV/AIDS stigma 248–9</td>
<td>injection infections 81</td>
</tr>
<tr>
<td>IDU (injecting drug use) intervention 92–5, 96–7</td>
<td>interventions, local diagnosis of 289</td>
</tr>
<tr>
<td>intervention studies 170–1</td>
<td>key indicators 115–16</td>
</tr>
<tr>
<td>key indicators 115–16</td>
<td>life expectancy with/without AIDS 162, 307</td>
</tr>
<tr>
<td>life expectancy with/without AIDS 162</td>
<td>Masaka intervention 255</td>
</tr>
<tr>
<td>life insurance incentivization 296–7</td>
<td>microfinance schemes 247</td>
</tr>
<tr>
<td>listed HIV epidemic drivers 285</td>
<td>OIs (opportunistic infections) 76–7, 78</td>
</tr>
<tr>
<td>Mema kwa Vijana intervention 255</td>
<td>PEPFAR-funded interventions 255</td>
</tr>
<tr>
<td>problems faced by government (Afrobarometer) 232</td>
<td>problems faced by government (Afrobarometer) 232</td>
</tr>
<tr>
<td>RESPECT study 193</td>
<td>sexually transmitted HIV 11</td>
</tr>
<tr>
<td>sexually transmitted infections 50</td>
<td>sexually transmitted infections 50</td>
</tr>
<tr>
<td>unmet need for family planning 165</td>
<td>TASO (AIDS Support Organization) 234–5</td>
</tr>
<tr>
<td>voluntary HIV testing and counseling uptake at community level 248</td>
<td>unmet need for family planning 165</td>
</tr>
<tr>
<td>VSL (Value of a Statistical Life) approach 170–1</td>
<td>UNAIDS 185–6, 188–9, 205, 235–6, 346</td>
</tr>
<tr>
<td>Tanzanian AIDS Commission 285</td>
<td>cost of saving life 205–6</td>
</tr>
<tr>
<td>Tanzanian epidemic 283</td>
<td>founding of 61</td>
</tr>
<tr>
<td>targeting strategy 312</td>
<td>improved investment approach 194–5</td>
</tr>
<tr>
<td>technologies 329</td>
<td>investment returns 188</td>
</tr>
<tr>
<td>temporary sexual relationships as HIV epidemic driver 285</td>
<td>and male circumcision 62</td>
</tr>
<tr>
<td>tenofvir 126</td>
<td>modes of transmission 66–7</td>
</tr>
<tr>
<td>test-and-treat strategy see ART</td>
<td>program enablers 194–5</td>
</tr>
<tr>
<td>Thai RV144 vaccine 303, 326</td>
<td>UNAIDS Global Plan 90</td>
</tr>
<tr>
<td>Thematic Panel Discussion 214</td>
<td>UNAIDS Investment Framework analysis 90</td>
</tr>
<tr>
<td>Togo</td>
<td>UNAIDS MOT (Modes of Transmission) model 81</td>
</tr>
<tr>
<td>blood supply testing 86</td>
<td>UNAIDS (United Nations Joint Programme on HIV/AIDS) 108–9</td>
</tr>
</tbody>
</table>
UNDP (Joint United Nations Programme on HIV/AIDS) 346
unexamined metaphors 281–6
UNGASS 189
unintended pregnancies 197
unit costs per country 272–3
United Nations
General Assembly Political Declaration on HIV/AIDS xix, 74
Security Council Resolution on HIV/AIDS xix
United Nations High-Level Meeting on AIDS, Thematic Panel Discussion 214
United Nations Non-Communicable Disease Summit (2011) 61
United States, HIV prevalence 153
universal HIV testing 183, 191–2, 206
adults 193
universal precautions intervention 186
vaccine research and development 7, 299–312, 321–7
accomplishments to date 300–1
annual investment in 303–5, 321
anti-retroviral therapy 330
benefit-cost analysis 304–9
of accelerating 309–12
continued investment 308–9
benefit-cost ratios 330
development history 302–4
development start 233
funding sources 300
infections averted benefits 308
investment priorities 328–9
investments 334
Nobel Laureate Economist Expert Panel findings on 337–9
operational protocols 302
and productivity levels 311
prospects 302–4
R&D 300–4
research agenda 301–2
research developments source 313
secondary infection prevention 311
and social value 330
spending 300
varying average costs 294–5
Vassall, Anna 6
VCT (voluntary counseling and testing) see HTC
Vesicular Stomatitis Virus 313
viral load and HIV risk 126, 151
monitoring 179
Voices of the Poor project 196
VSL (Value of Statistical Life) approach 170–1
Watts, Charlotte 6
Whiteside, Alan 4
WHO (World Health Organization)
on alcohol taxation 243
Options 5, 162–3
program 162
women living with HIV, unintended pregnancies 197
World Bank
decline in benefit-cost analysis 190
health funding evaluation 233, 235–6
results-based funding (RBF) programs 202–3
structural adjustment lending 231–3
Voices of the Poor 196
World Development Report 1993, Investing in Health 203
WTP (willingness to pay) 170–1
ZAC (Zanzibar AIDS Commission) 283
Zambia
Abuja target 202
alcohol tax 262–3
development indicators 227
health priority survey 230–1
health worker shortage 196
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 34, 66–7, 196
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
male circumcision 23–5
OIs (opportunistic infections) 76–7, 78
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
unmet need for family planning 165
Voices of the Poor project 196
Zaric, G. S. 295
ZDV (Zidovudine) program 89, 162–3, 175
zero uptake
and benefit-cost ratios 151
counterfactual 135, 136
simulation results 139
Zimbabwe
alcohol tax 262–3
development indicators 227
health priority survey 230–1
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 19, 301, 324
HIV/AIDS stigma 248–9
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 23–5
maternal/infant life expectancy 111
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
voluntary HIV testing and counseling uptake at community level 248
Zuma, Jacob 195